{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:39:35Z","timestamp":1788925175228,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejmech.2026.118764","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:34:57Z","timestamp":1773765297000},"page":"118764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Covalent JAK3 inhibitors based on 2-arylamino and 7H-pyrrolo[2,3-d]pyrimidine scaffold: design, synthesis, and biological evaluation for the potential treatment of bortezomib-resistant multiple myeloma"],"prefix":"10.1016","volume":"310","author":[{"given":"Liangliang","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxuan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafiseh","family":"Bolghanabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0504-6182","authenticated-orcid":false,"given":"Lixue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejmech.2026.118764_bib1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.medcli.2018.10.020","article-title":"JAK-STAT inhibitors for the treatment of immunomediated diseases. Inhibidores de la v\u00eda de se\u00f1alizaci\u00f3n JAK-STAT en el tratamiento de las enfermedades inmunomediadas","volume":"152","author":"Serra L\u00f3pez-Matencio","year":"2019","journal-title":"Med. Clin."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118764_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.molmed.2020.06.007","article-title":"JAK-STAT targeting offers novel therapeutic opportunities in sepsis","volume":"26","author":"Clere-Jehl","year":"2020","journal-title":"Trends Mol. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118764_bib3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.immuni.2012.03.016","article-title":"Inborn errors of human JAKs and STATs","volume":"36","author":"Casanova","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2026.118764_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112155","article-title":"Janus kinases (JAKs): the efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders","volume":"192","author":"Xu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118764_bib5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.phrs.2017.10.001","article-title":"Linking energy sensing to suppression of JAK-STAT signalling: a potential route for repurposing AMPK activators?","volume":"128","author":"Speirs","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118764_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol."},{"issue":"24","key":"10.1016\/j.ejmech.2026.118764_bib7","doi-asserted-by":"crossref","first-page":"13976","DOI":"10.1074\/jbc.271.24.13976","article-title":"Expression of Janus kinase 3 in human endothelial and other non-lymphoid and non-myeloid cells","volume":"271","author":"Verbsky","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118764_bib8","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1182\/blood.V87.8.3151.bloodjournal8783151","article-title":"Murine JAK3 is preferentially expressed in hematopoietic tissues and lymphocyte precursor cells","volume":"87","author":"Gurniak","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118764_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118764_bib10","first-page":"282","article-title":"ERBB1\/EGFR and JAK3 tyrosine kinases as potential therapeutic targets in high-risk multiple myeloma","volume":"2","author":"Uckun","year":"2022","journal-title":"Onco (Basel)"},{"issue":"12","key":"10.1016\/j.ejmech.2026.118764_bib11","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1182\/blood-2008-06-164368","article-title":"Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models","volume":"113","author":"Cornejo","year":"2009","journal-title":"Blood"},{"issue":"9880","key":"10.1016\/j.ejmech.2026.118764_bib12","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/S0140-6736(13)61114-9","article-title":"Tofacitinib for rheumatoid arthritis","volume":"381","author":"Gremese","year":"2013","journal-title":"Lancet."},{"issue":"13","key":"10.1016\/j.ejmech.2026.118764_bib13","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1021\/jm200326p","volume":"54","author":"William","year":"2011","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118764_bib14","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/acs.jmedchem.6b01694","article-title":"Design of a janus kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans","volume":"60","author":"Thorarensen","year":"2017","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2026.118764_bib15","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1021\/acs.jmedchem.5b00710","article-title":"Development of selective covalent janus kinase 3 inhibitors","volume":"58","author":"Tan","year":"2015","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118764_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2011.46","article-title":"The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma","volume":"1","author":"Derenzini","year":"2011","journal-title":"Blood Cancer J."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118764_bib17","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/1078-0432.CCR-18-1047","article-title":"Cerdulatinib pharmacodynamics and relationships to tumor response following oral dosing in patients with relapsed\/refractory B-cell malignancies","volume":"25","author":"Coffey","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.ejmech.2026.118764_bib18","doi-asserted-by":"crossref","first-page":"13268","DOI":"10.1021\/acs.jmedchem.4c02288","article-title":"Design and synthesis of novel dual inhibitors for JAK3 and TEC kinases in autoimmune disorders","volume":"68","author":"Cui","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118764_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118448","article-title":"Deep seeking covalent DNA encoded library for novel JAK3 inhibitor discovery","volume":"132","author":"Chen","year":"2026","journal-title":"Bioorg. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118764_bib20","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118764_bib21","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.3389\/fimmu.2018.02431","article-title":"Update on PD-1\/PD-L1 inhibitors in multiple myeloma","volume":"9","author":"Jelinek","year":"2018","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118764_bib22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118764_bib23","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118764_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105330","article-title":"Design, synthesis, and biological evaluation of cyano-substituted 2,4-diarylaminopyrimidines as potent JAK3 inhibitors for the treatment of B-cell lymphoma","volume":"116","author":"Wu","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118764_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114607","article-title":"Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FAK inhibitors for the potential treatment of pancreatic cancer","volume":"241","author":"Zheng","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118764_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104385","article-title":"Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML","volume":"106","author":"Li","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"23-24","key":"10.1016\/j.ejmech.2026.118764_bib27","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1016\/j.bmc.2018.11.009","article-title":"The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M\/L858R inhibitors for NSCLC","volume":"26","author":"Chen","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118764_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113626","article-title":"Noncovalent EGFR T790M\/L858R inhibitors based on diphenylpyrimidine scaffold: design, synthesis, and bioactivity evaluation for the treatment of NSCLC","volume":"223","author":"Chen","year":"2021","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T18:43:51Z","timestamp":1776105831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426002096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":28,"alternative-id":["S0223523426002096"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118764","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Covalent JAK3 inhibitors based on 2-arylamino and 7H-pyrrolo[2,3-d]pyrimidine scaffold: design, synthesis, and biological evaluation for the potential treatment of bortezomib-resistant multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118764","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118764"}}